- Trials with a EudraCT protocol (2,650)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (72)
2,650 result(s) found for: Small.
Displaying page 1 of 133.
EudraCT Number: 2007-005245-37 | Sponsor Protocol Number: M06-880 | Start Date*: 2008-04-17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001259-34 | Sponsor Protocol Number: FoRT01/2016 | Start Date*: 2016-08-31 | ||||||||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | ||||||||||||||||||
Full Title: PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST) | ||||||||||||||||||
Medical condition: ROS1 positive non-small-cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004157-16 | Sponsor Protocol Number: CABinMET | Start Date*: 2018-02-21 | ||||||||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | ||||||||||||||||||
Full Title: Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation | ||||||||||||||||||
Medical condition: Stage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001331-36 | Sponsor Protocol Number: EORTC 08021 - ILCP | Start Date*: 2005-02-17 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A randomized phase III study of follow-up with or without Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer. | |||||||||||||
Medical condition: Non small cell lung cancer, advanced. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003495-35 | Sponsor Protocol Number: IEO S311/306 | Start Date*: 2007-06-05 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: PHASE II TRIAL OF BORTEZOMIB (VELCADE) IN COMBINATION WITH CHLORAMBUCIL IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTROMムS MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA. A MULTICENTER STUDY. | |||||||||||||
Medical condition: WALDENSTROMムS MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011895-31 | Sponsor Protocol Number: CLIN903 LCM201 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:STEBA BIOTECH | |||||||||||||
Full Title: EVALUATION OF THE SAFETY AND EFFICACY OF WST11 MEDIATED VASCULAR TARGETED PHOTODYNAMIC THERAPY ON OBSTRUCTING ENDOBRONCHIAL NON-SMALL CELL LUNG CANCER | |||||||||||||
Medical condition: Obstructive endobronchial non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003795-49 | Sponsor Protocol Number: IFCT-1603 | Start Date*: 2016-12-16 | |||||||||||||||||||||
Sponsor Name:IFCT | |||||||||||||||||||||||
Full Title: A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung can... | |||||||||||||||||||||||
Medical condition: Small Cell Lung Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001263-12 | Sponsor Protocol Number: FoRT01/2014 | Start Date*: 2014-08-07 | |||||||||||
Sponsor Name:Fondazione Ricerca Traslazionale (FoRT) | |||||||||||||
Full Title: Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS) | |||||||||||||
Medical condition: Pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004722-27 | Sponsor Protocol Number: ICT-BEM-2004-01 | Start Date*: 2005-05-12 | |||||||||||
Sponsor Name:Instituto Científico y Tecnológico de Navarra, S.A. | |||||||||||||
Full Title: Randomised, open, multicenter, sequential trial assessing the safety and efficacy of bemiparin on the response to the treatment in patients diagnosed with localized small cell carcinoma of the lung. | |||||||||||||
Medical condition: Small cell carcionoma of the lung medDRA CLASSIFICATION CODE: PT 10041071 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005942-22 | Sponsor Protocol Number: MK8669-021 | Start Date*: 2009-01-15 | |||||||||||
Sponsor Name:MERCK & CO., INC. | |||||||||||||
Full Title: A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations. | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007139-26 | Sponsor Protocol Number: S075LBH501 | Start Date*: 2008-04-17 | |||||||||||
Sponsor Name:SENDO TECH | |||||||||||||
Full Title: A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC) | |||||||||||||
Medical condition: SCLC patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005614-29 | Sponsor Protocol Number: CC-486-NSCL-001 | Start Date*: 2015-11-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembroliz... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) ES (Completed) GR (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002708-33 | Sponsor Protocol Number: POP 01 | Start Date*: 2007-07-19 | |||||||||||
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | |||||||||||||
Full Title: RANDOMIZED PHASE III TRIAL OF PREOPERATIVE VERSUS POSTOPERATIVE CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER NSCLC | |||||||||||||
Medical condition: Neoadjuvant treatmento for early stage non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002552-24 | Sponsor Protocol Number: PKAPIR | Start Date*: 2016-12-16 | |||||||||||
Sponsor Name:Centre Georges François Leclerc | |||||||||||||
Full Title: Pemetrexed (Alimta®) in maintenance in patients with impaired renal function: multicenter randomized Phase 4 study comparing two strategies for dose calculation | |||||||||||||
Medical condition: Patients with non-small lung cell cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004847-47 | Sponsor Protocol Number: DOCET_L_01704 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:Jeroen Bosch - Groot Ziekengasthuis | |||||||||||||
Full Title: A phase II study of docetaxel/carboplatin as secondline treatment in patients with refractory or relapsed SCLC | |||||||||||||
Medical condition: patients with refractory or relapsed small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001105-96 | Sponsor Protocol Number: EMR62202-046 | Start Date*: 2004-09-14 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing adva... | |||||||||||||
Medical condition: Epidermal growth factor receptor-expressing advanced non-small cell lung cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005941-39 | Sponsor Protocol Number: 646-007-00 | Start Date*: 2008-06-30 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer" | |||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) SE (Completed) DK (Completed) FR (Completed) NL (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008920-34 | Sponsor Protocol Number: 09.01 | Start Date*: 2009-03-19 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Induction chemotherapy with Carboplatin and Navelbine Oral® followed by concomitant Navelbine Oral® and irradiation in local-regionally advanced non-small cell lung cancer. A randomized phase II s... | |||||||||||||
Medical condition: Local-regionally advanced non-small cell lung cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004963-68 | Sponsor Protocol Number: 26866138-LUC-2006 | Start Date*: 2007-10-16 | |||||||||||
Sponsor Name:Prof Vassilis Georgoulias | |||||||||||||
Full Title: A Phase II, Open-Label Trial of Bortezomib (Velcade®) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | |||||||||||||
Medical condition: First Line treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008921-30 | Sponsor Protocol Number: 09.02 | Start Date*: 2009-03-17 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Concomitant Tarceva® and irradiation in patients in local-regionally advanced non-small cell lung cancer. A phase II study | |||||||||||||
Medical condition: Local-regionally advanced non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.